Related Experiment Videos
[Clinical evaluation of ceftizoxime in the pediatric infections (author's transl)]
Insights
Ceftizoxime (CZX) demonstrated high effectiveness (94.1%) in treating bacterial infections in children. This parenteral antibiotic showed a good safety profile, making it a potential first-choice treatment for pediatric infections.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Bacteriology
Context:
- Bacterial infections pose a significant health risk in pediatric populations.
- Parenteral antibiotics are crucial for treating severe pediatric infections.
- Evaluating novel antibiotic efficacy and safety is essential for clinical practice.
Purpose:
- To assess the efficacy and safety of Ceftizoxime (CZX) in treating pediatric bacterial infections.
- To determine the pharmacokinetic profile of CZX in children, including serum half-life and cerebrospinal fluid penetration.
- To identify the spectrum of bacterial pathogens susceptible to CZX in pediatric cases.
Summary:
- Ceftizoxime (CZX) was evaluated in 24 children with suspected bacterial infections, with 17 confirmed cases.
- An overall efficacy rate of 94.1% was observed, with successful treatment in 16 out of 17 confirmed infections.
- Common diagnoses included pneumonia, acute enterocolitis, and septicemia, caused by pathogens like Staphylococcus aureus and Haemophilus influenzae.
- CZX exhibited a serum half-life of 1.36 hours and achieved therapeutic levels in cerebrospinal fluid.
- No severe adverse reactions were reported, indicating a favorable safety profile.
Impact:
- Ceftizoxime (CZX) shows promise as a highly effective and safe first-line parenteral antibiotic for pediatric infections.
- The study provides valuable data on CZX's clinical utility and pharmacokinetic properties in children.
- Findings support the consideration of CZX in treatment guidelines for pediatric bacterial infections.
Abstract:
Ceftizoxime (FK 749, CZX) was evaluated in 24 children with a suspicion of bacterial infection. Of the 17 confirmed bacterial infections, 16 were shown to be effective (effective rate, 94.1%). The diagnosis included acute pharyngitis (2), pneumonia (6), staphylococcal empyema (1), cervical purulent lymphadenitis (2), acute enterocolitis (2), acute pyelonephritis (1), SSSS (1) and suspected septicemia (2). The etiological pathogens recovered were Streptococcus anginosus (1), Streptococcus pneumoniae (1), Staphylococcus aureus (2), Haemophilus influenzae (3), enteropathogenic Escherichia coli (1) etc. A case of suspected Pseudomonas aeruginosa septicemia was not effectively treated with CZX. The serum half-life of CZX was 1.36 hours after intravenous bolus infection. A cerebrospinal fluid level of CZX was 6.2 mcg/ml 1 hour after intravenous bolus injection of 1 g (23.8 mg/kg) in a child with inflamed meninges. No severe adverse reaction was encountered with the CZX therapy. The data suggest that CZX is an excellent candidate for the first choice parenteral antibiotic in the pediatric infections.